drugset / Trial / NCT07128251
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Phase 2
Not yet recruiting
47 enrolled
Anhui Provincial Hospital
First Affiliated Hospital of Guangxi Medical University · collabHenan Provincial People's Hospital · collabQilu Hospital of Shandong University · collabShanxi Province Cancer Hospital · collabThe Second Affiliated Hospital of Harbin Medical University · collabXi'an International Medical Center Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable, non-metastatic HCC. The primary endpoint is PFS as assessed by the investigator based on RECIST v1.1 criteria.
Timeline
- Start
- 2025-08-20
- Primary completion
- 2028-01-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Iparomlimab and Tuvonralimab | Unknown | 7.5 mg/kg | Intravenous |